Clinical trials: Atezolizumab
Lung Cancer
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
- Trial name
- BECOME (NCT05055908)
- Testing
- Pemetrexed plus Pembrolizumab, Pembrolizumab, Pemetrexed
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic…
- Trial name
- SKYSCRAPER-01 (NCT04294810)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 134 sites in United States, Australia and 21 more
- Volunteers
- 620 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
The gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations in patients with advanced lung cancer through fecal microbiota transplantation from healthy…
- Trial name
- NCT04924374
- Testing
- Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC)
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety…
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
- Trial name
- LB-LR1109 (NCT06332755)
- Testing
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- LG Chem
HPV-Associated Cancers
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
This is a Phase 1/1b open-label dose escalation trial of Ad/MG1-E6E7 and sequential treatment with atezolizumab in patients with HPV associated cancers. This study will consist of two arms.
- Trial name
- Kingfisher (NCT03618953)
- Testing
- Ad-E6E7, MG1-E6E7, Atezolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Turnstone Biologics, Corp.
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy…
- Trial name
- TAIL (NCT03285763)
- Testing
- Atezolizumab
- Where
- 111 sites in Argentina, Brazil and 22 more
- Volunteers
- 619 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma, Pancreatic Ductal
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone…
- Trial name
- IMCODE003 (NCT05968326)
- Testing
- Autogene cevumeran, Atezolizumab, mFOLFIRINOX
- Where
- 87 sites in United States, Belgium and 8 more
- Volunteers
- 260 people
- Sponsor
- Genentech, Inc.
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03206047
- Testing
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine
- Where
- 17 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine.
- Trial name
- NCT03179943
- Testing
- Atezolizumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
Endometrial Cancer
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent…
- Trial name
- EndoMAP (NCT04486352)
- Testing
- Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib
- Where
- 21 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alliance Foundation Trials, LLC.
Metastatic Solid Tumors
First in Human Study of M6223
The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks…
- Trial name
- NCT04457778
- Testing
- M6223, Bintrafusp alfa
- Where
- 4 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Oropharynx Cancer, Stage I
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable).
- Trial name
- NCT06254911
- Testing
- Atezolizumab, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Solid Tumors
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
This study is being conducted to evaluate efficacy parameters (disease free survival [DFS] and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after…
- Trial name
- IMperator (NCT06331598)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 3 sites in Spain
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Melanoma Cancer
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy…
- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer
- Trial name
- NCT03693014
- Testing
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT04984811
- Testing
- efineptakin alfa, Atezolizumab
- Where
- 22 sites in United States
- Volunteers
- 33 people
- Sponsor
- NeoImmuneTech
Non-squamous Non-small-cell Lung Cancer
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
- Trial name
- NCT04958811
- Testing
- Tiragolumab, Atezolizumab, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Georgetown University
Non Small Cell Lung Cancer, Microbiome
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics.
- Conditions
- Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy
- Trial name
- NCT04136470
- Testing
- Collection of stool, blood (PBMC) and biopsy (FFPE)
- Where
- 10 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Ardigen
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This is a multi-center observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer(NSCLC) or extensive disease small cell lung cancer(ED-SCLC).
- Trial name
- NCT04501497
- Where
- 148 sites in Japan
- Volunteers
- 1,221 people
- Sponsor
- Chugai Pharmaceutical
Breast Cancer
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC).
- Trial name
- NCT02708680
- Testing
- Entinostat, Atezolizumab
- Where
- 29 sites in United States, Georgia
- Volunteers
- 89 people
- Sponsor
- Syndax Pharmaceuticals